The Companion Diagnostics (CDx) Market Forecast 2016-2026

コンパニオン診断(CDx)の世界市場予測2016-2026

◆タイトル:The Companion Diagnostics (CDx) Market Forecast 2016-2026
◆商品コード:VGAIN6041538
◆調査・発行会社:visiongain
◆発行日:2016年3月
◆ページ数:192
◆レポート形式:PDF / 英語
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名利用)GBP1,999 ⇒換算¥295,852見積依頼/購入/質問フォーム
Five UserGBP2,999 ⇒換算¥443,852見積依頼/購入/質問フォーム
Site License(全社内共有可)GBP4,999 ⇒換算¥739,852見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM(デジタル著作権管理)付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

【レポートの概要】

本調査レポートでは、"コンパニオン診断(CDx)の世界市場予測2016-2026"について調査・分析し、レポートサマリー、世界市場規模・市場予測、地域別市場分析、主要国別市場分析、市場環境分析、研究開発パイプライン分析、主要企業分析、結論などの情報をお届けいたします。

What can be expected from the Companion Diagnostics market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2026, assessing data, trends, opportunities and prospects there.
Our 192-page report provides 127 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales across the whole companion diagnostics market. You will see financial results, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.

Forecasts from 2016-2026 and other analyses show you commercial prospects
Besides revenue forecasting to 2026, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.

The report also includes will find revenue forecasts to 2026 for the following submarkets in the companion diagnostics market:
• Theranostics
• Other Companion Diagnostics

Additionally, this report includes a forecast to 2026 for the global in vitro diagnostics market.

The report also includes will find revenue forecasts to 2026 for the following national and regional markets for companion diagnostics:
• US
• Germany
• France
• Italy
• Spain
• UK
• Japan
• China
• India
• Russia
• Brazil
• South Korea

The report provides detailed profiles of key companies operating within the companion diagnostics market:
• F. Hoffmann-La Roche Ltd
• Qiagen N.V.
• Abbott Laboratories
• Agilent Technologies
• Myriad Genetics
• bioMerieux
• Thermo Fisher Scientific

Leading companies and potential for market growth
Overall revenue for the Companion Diagnostics market will reach $10.5bn in 2020, our work forecasts. We predict strong revenue growth through to 2026. Advances in cellular and tissue research, an improving regulatory landscape, strong support from governments in multiple regions and the launch of several new therapies in areas of unmet clinical need will drive sales to 2026.

Our work analyses the key companies in the market. See visiongain’s analysis of 7 leading companies, including these:
• F. Hoffmann-La Roche Ltd
• Qiagen N.V.
• Abbott Laboratories
• Agilent Technologies
• Myriad Genetics
• bioMerieux
• Thermo Fisher Scientific

A company profile gives you the following information where available:
• Discussion of a company’s activities and outlook
• Historic revenue, analysis and discussion of company performance over the past 5 years
• Analysis of major products currently on the market
• Acquisitions and strategic partnerships

Discover capabilities, progress, and commercial prospects, helping you stay ahead.

【レポートの目次】

1. Report Overview
1.1 The Companion Diagnostics Market Overview
1.2 Companion Diagnostics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain

2. Introduction to Companion Diagnostics
2.1 The Foundation of Personalised Medicine
2.2 Personalised Medicine: Changing the Patient Treatment Paradigm
2.3 In Vitro Diagnostic (IVD) Tests
2.3.1 Companion Diagnostics: A Type of IVD
2.3.2 Differences between Companion Diagnostics and Theranostics
2.3.3 Biomarkers to Companion Diagnostics
2.3.4 Genomic Biomarkers
2.3.5 Genomic Oncology Biomarkers
2.4 Regulations in the Companion Diagnostics Market
2.4.1 FDA’s Final Guidance on Companion Diagnostics
2.4.2 LDTs: A Changing Landscape
2.5 Encouraging the Contemporaneous Development of Companion Diagnostics

3. The World Companion Diagnostics Market, 2016-2026
3.1 Scope and Limitations
3.2 The Global Companion Diagnostics Market, 2014 and 2015
3.3 The Global Companion Diagnostics Market Sales Forecast, 2016-2026
3.4 Companion Diagnostics: Growth Outpacing the Rest of the IVD Market
3.5 Companion Diagnostics: Increasing Market Share of the IVD Market
3.6 The Companion Diagnostics Market by Submarket, 2014
3.7 Theranostics: Fastest Growing Segment of the CDx Market
3.8 Changing Market Shares of the Leading Companion Diagnostics Submarkets, 2015-2025

4. Leading National Markets for Companion Diagnostics, 2016-2026
4.1 The Leading National Markets for Companion Diagnostics: Led by 3 Dominant Markets in 2014 & 2015
4.2 The Leading National Markets for Companion Diagnostics Sales Forecast, 2016-2026
4.2.1 Changing Market Shares of Leading National Markets, 2016-2026
4.3 The US Companion Diagnostics Market Sales Forecast, 2016-2026
4.3.1 The US Will Continue to Dominate the Market
4.4 The EU5 Companion Diagnostics Sales Market, 2014
4.4.1 The EU5 Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.2 Changing Market Shares of the EU5 Companion Diagnostics Market
4.4.3 The German Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.4 The French Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.5 The Italian Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.6 The Spanish Companion Diagnostics Market Sales Forecast, 2016-2026
4.4.7 The UK Companion Diagnostics Market Sales Forecast, 2016-2026
4.5 The Japanese Companion Diagnostics Market Sales Forecast, 2016-2026
4.5.1 Japan’s Medical Technology Regulatory Process Reducing Time to Market
4.6 The Chinese Companion Diagnostics Market Sales Forecast, 2016-2026
4.6.1 Cancer Rates will Drive Adoption of Companion Diagnostic Tests
4.7 The Indian Companion Diagnostics Market Sales Forecast, 2016-2026
4.8 The Brazilian Companion Diagnostics Market Sales Forecast, 2016-2026
4.9 The Russian Companion Diagnostics Market Sales Forecast, 2016-2026
4.10 The South Korean Companion Diagnostics Market Sales Forecast, 2016-2026
4.11 The Rest of the World Companion Diagnostics Market Sales Forecast, 2016-2026

5. The Companion Diagnostics Market: Marketed Products and Pipeline Partnerships
5.1 Biomarkers: At the Forefront of Companion Diagnostics Development
5.2 US FDA Approved Companion Diagnostic Tests, 2016
5.3 Oncology Continues to Dominate the R&D Pipeline of Companion Diagnostics
5.4 Expensive Cancer Therapies Encourages the Development of CDx
5.5 Companion Diagnostic/Pharma Partnerships, 2013-2014

6. Business Models and Stakeholders in the Companion Diagnostics Market
6.1 Business Models for the Development of Companion Diagnostics
6.1.1 The Partnership Model is the Most Practiced Method
6.1.2 The Stand-Alone Model: Licensing an IP
6.1.3 The One Stop Shop Model: An Approach by Big Pharma
6.1.4 Using Contract Diagnostics Organisations (CDO): An Emerging Trend
6.2 Factors Driving Companies to Enter the Companion Diagnostics Market
6.3 Stakeholders Influencing the Companion Diagnostics Market
6.3.1 Pharmaceutical Companies and Diagnostic Manufacturers
6.3.2 Regulatory Authorities
6.3.3 Testing Laboratories
6.3.4 Physicians and Patients
6.3.5 Payers
6.4 Companion Diagnostics Competitive Landscape, 2016

7. Leading Companies in the Companion Diagnostics Market 2015
7.1 Roche: Global Diagnostics Leader
7.1.1 Ventana Medical Systems (Roche)
7.1.2 Sales and Recent Performance Analysis, 2014
7.1.3 Roche Diagnostics by Region, 2014
7.1.4 Roche: Internal Growth
7.1.5 Approval of Tarceva and Cobas EGFR Mutation Test
7.1.6 Roche’s Portfolio of Companion Diagnostic Project Pipeline and Marketed Companion Diagnostics, 2015
7.1.7 Ventana Companion Diagnostics: Robust New Prototype Assays
7.1.8 Recent Companion Diagnostic External Collaborations, 2014-2015
7.1.8.1 Ventana/Genmab
7.1.8.2 Ferring/ Roche: CDx Development for Infertility Treatment
7.1.8.3 MedImmune (AstraZeneca)/Ventana: Assay for NSCLC Targeted Clinical Trials
7.1.8.4 Merck/Ventana: CDx for an Undisclosed Target
7.1.8.5 AstraZeneca/Roche: CDx to Support Target Drug AZD9291
7.1.8.6 Boehringer Ingelheim/Roche
7.1.8.7 ImmunoGen/ Ventana
7.1.8.8 Foundation Medicine/Roche
7.1.9 Roche: Major M&A Activity and Strategic Partnerships Strengthen Position as Diagnostic Market Leader
7.1.9.1 Genia Acquisition to Strengthen DNA Sequencing Capabilities
7.1.9.2 IQuum Acquisition Allows Movement into POC MDx Market
7.1.9.3 Seragon Acquisition Strengthens Leading Position in Oncology
7.1.9.4 Santaris Acquisition Enchances Roche’s Position in RNA-Targeted Drugs Market
7.1.9.5 Bina Acquisition Brings Big Data Solution to Support NGS Development
7.1.9.6 Dutalys Acquisition Enhances Roche’s mAB Portfolio
7.1.9.7 Ariosa Acquisition Adds NIPT to Diagnostic Portfolio
7.1.9.8 Foundation Medicine Deal Enhances Personalised Medicine Capabilities for Oncology
7.1.9.9 Signature and CAPP Acquisitions Strengthen Circulating DNA Testing Abilities
7.1.9.10 GENEWEAVE and Kapa Acquisitions Help Cement Roche’s Position as the Market Leader
7.2 Qiagen N.V.: Leading CDx Collaborator with Pharmaceutical Companies
7.2.1 Sales and Recent Performance Analysis, 2010-2015
7.2.2 Qiagen Sales By Region
7.2.3 Companion Diagnostics Collaboration Agreements with Pharma, 2015
7.2.3.1 Collaboration with Eli Lilly
7.2.3.2 Collaboration with AstraZeneca
7.2.3.3 Collaboration with Astellas Pharma
7.2.3.4 Collaboration with Novartis
7.2.3.5 Collaboration with Array BioPharma
7.2.3.6 Collaboration with Protagen
7.3 Abbott Molecular: An Established Competitor
7.3.1 Sales and Recent Performance Analysis, 2012-2015
7.3.2 Abbott Molecular: Expansive Oncology Biomarker Pipeline
7.3.3 Recent Activity and Collaborations
7.3.3.1 Collaboration with Merck
7.3.3.2 Collaborative Efforts with Idera
7.3.3.3 Collaboration with AstraZeneca
7.4 Agilent Technologies (Dako)
7.4.1 Life Sciences and Diagnostics Business
7.4.2 Agilent Life Sciences and Diagnostics, Sales and Recent Performance Analysis, 2015
7.4.3 Agilent: Next Generation Sequencing Platforms
7.4.4 Recent Companion Diagnostic Collaborations
7.4.4.1 Agilent/ Merck: Several Cancer Collaborations
7.4.4.2 Agilent/Pfizer: An Ongoing Collaboration
7.4.4.3 Agilent/Bristol-Myers Squibb
7.5 Myriad Genetics
7.5.1 Acquisition of Myriad RBM: Increases the Company’s Market Share of Companion Diagnostics
7.5.2 Companion Diagnostic Service Offerings
7.5.3 Sales and Recent Performance Analysis, 2013-2014
7.5.3.1 myRisk: Next Generation Hereditary Cancer Testing
7.5.4 Myriad Genetics Recent Collaborations
7.5.4.1 Myriad/AstraZeneca: Premarket Approval Application
7.5.4.2 Acquisition of Crescendo Bioscience: Entry into the Autoimmune Market
7.5.4.3 Myriad/ TESARO Companion Collaboration
7.5.4.4 Collaboration with AbbVie
7.6 BioMérieux
7.6.1 Sales and Recent Performance Analysis, 2010-2015
7.6.2 Sales by Region, 2014
7.6.3 Sales by Technology, 2015
7.6.4 Companion Diagnostics: Recent M&A Activity & Collaboration
7.6.4.1 Collaboration with Gilead Sciences
7.6.4.2 Collaboration with Ipsen
7.6.4.3 Collaboration with Merck
7.6.4.4 Collaborations with GSK and Novartis
7.6.4.5 Mergers, Acquisitions and Collaborations
7.6.5 bioTheranostics: Subsidiary for Oncology Diagnostics
7.7 Thermo Fisher Scientific
7.7.1 Sales and Recent Performance Analysis, 2013-2014
7.7.1.1 Thermo Fisher Scientific Sales by Region, 2015
7.7.2 Recent Collaborations and Acquisitions
7.7.2.1 Acquisition of Life Technologies
7.7.2.2 Acquisition of Prionics
7.7.2.3 Acquisition of Advanced Scientifics, Inc.
7.7.2.4 Acquisition of Alfa Aesar
7.7.2.5 Affymetrix: Thermo Fisher’s Next Target
7.7.2.6 Thermo Fisher: Developing a ‘Universal’ Companion Diagnostics Using Next Generation Sequencing
7.7.2.7 Thermo Fisher: Life Technologies Collaborates with Merck Serono
7.7.2.8 Thermo Fisher Scientific Collaboration with Pfizer and Novartis to Offer NGS-Based Companion Test for NSCLC

8. Qualitative Analysis of the Companion Diagnostics Market, 2016-2026
8.1 SWOT Analysis of the Companion Diagnostics Market
8.2 Strengths
8.2.1 A CDx Strategy Decreases the Length of Approval Process
8.2.2 Premium Prices for Companion Diagnostics
8.2.3 A CDx Development Strategy Can Generate More Effective Drugs
8.2.4 Therapeutics Tied with CDx can have Safer Profiles
8.2.5 Reducing the Cost of Healthcare
8.2.6 Increased Regulatory Scrutiny on Marketed Drugs
8.2.7 Targeted Therapies Will Drive the CDx Market
8.3 Weaknesses
8.3.1 Reimbursement Challenges
8.3.2 Lack of Clear Regulatory Guidelines
8.3.3 Capital Intensity is High
8.4 Opportunities
8.4.1 Fast-growing Emerging Markets
8.4.2 Next Generation Sequencing
8.4.3 Many New CDx/ Pharma Company Partnerships
8.5 Threats
8.5.1 Complex Business Models and Business Partnerships
8.5.2 Medical Device Excise Tax
8.6 Porter’s Five Forces Analysis of the Companion Diagnostics Market
8.6.1 Rivalry Among Competitors [High]
8.6.2 Power of Suppliers [High]
8.6.3 Power of Buyers [Medium]
8.6.4 Threat of New Entrants [Medium]
8.6.5 Threat of Substitutes [High]

9. Conclusions
9.1 Overview
9.2 Theranostics: A Fast Growing Market
9.3 Leading Companion Diagnostic Companies
9.4 Pharmaceutical/Diagnostic Partnership Model
9.5 Oncology is the Leading Therapy Area Driving Companion Diagnostics
9.6 Commercial Drivers of the Companion Diagnostics Market
9.7 Commercial Restraints of the Companion Diagnostics Market
9.8 Concluding Remarks

10. Glossary

Appendix
Visiongain’s Bespoke Research Service
Some Associated Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form

List of Tables
Table 1.1 The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2014-2026
Table 1.2 The CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2020-2026
Table 2.1 Examples of Clinically Relevant Cancer Biomarkers, 2016
Table 3.1 The World IVD Market: Revenue ($bn) and Market Share (%) by Segment, 2014
Table 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 3.3 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 3.4 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 3.5 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 3.6 CDx Market Share (%) in the IVD Market, 2014, 2020, 2026
Table 3.7 The World Companion Diagnostics Market: Revenue ($bn) and Market Share (%) by Submarket, 2014
Table 3.8 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2014-2020
Table 3.9 The World Companion Diagnostics Market by Submarket: Revenue ($bn), AGR (%) and CAGR (%), by Submarket, 2020-2026
Table 3.10 Revenue ($bn) and Market Share (%) of Submarkets in the CDx Market, 2014, 2020, 2026
Table 4.1 The Leading National Markets for CDx: Sales ($m), Market Share (%), 2014
Table 4.2 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2014-2020
Table 4.3 The Leading National Companion Diagnostics Market Forecast: Revenues ($m), AGR (%) and CAGR (%), 2020-2026
Table 4.4 Revenue ($bn) and Market Share (%) of the National Markets in the CDx Market, 2014, 2020, 2026
Table 4.5 The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2014-2020
Table 4.6 The US CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2020-2026
Table 4.7 The EU5 CDx Market Forecast: Revenue ($bn) and Market Share (%), 2014
Table 4.8 The EU5 Companion Diagnostic National Market Forecasts: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.9 The EU5 Companion Diagnostic National Market Forecasts: Revenues ($bn), AGR (%) and CAGR (%), 2020-2026
Table 4.10 Market Share (%) of Each EU5 Region in the CDx Market, 2014, 2020, 2026
Table 4.11 The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.12 The German CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 4.13 The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.14 The French CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 4.15 The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.16 The Italian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Table 4.17 The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.18 The Spanish CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 4.19 The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.20 The UK CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 4.21 The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2014-2020
Table 4.22 The Japanese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) 2020-2026
Table 4.23 The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.24 The Chinese CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 4.25 The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.26 The Indian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 4.27 The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.28 The Brazilian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 4.29 The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.30 The Russian CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 4.31 The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.32 The South Korean CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 4.33 The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2014-2020
Table 4.34 The Rest of the World CDx Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2020-2026
Table 5.1 List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2016
Table 5.1 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2016
Table 5.1 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2016
Table 5.1 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2016
Table 5.1 (Cont’d) List of FDA-Approved Drugs with Pharmacogenomic Biomarker Information in Their Labelling, 2016
Table 5.2 List of Cleared or Approved Companion Diagnostic Devices and Their Complementary Therapeutic Drug, 2015
Table 5.3 List of CDx Diagnostic/Pharma Partnerships, 2013-2014
Table 6.1 List of Companies in the Companion Diagnostics Market, 2016
Table 6.1 (Cont’d) List of Companies in the Companion Diagnostics Market, 2016
Table 7.1 Roche Diagnostics: Revenue ($bn) and Revenue Share (%) by Business Area, 2014
Table 7.2 Roche Diagnostics: Revenue ($bn), Revenue Shares (%) by Region, 2014
Table 7.3 Roche: Major Companion Diagnostic Projects, 2015
Table 7.4 Roche Diagnostics: List of Marketed Companion Diagnostics, 2015
Table 7.5 Qiagen: Revenue ($bn), Net Income ($bn) and Profit Margin, 2010-2015
Table 7.6 Qiagen: Revenue ($m), Revenue Share (%) by Geography, 2012-2015
Table 7.7 Abbott: Revenue ($bn) by Reported Segment, 2012-2015
Table 7.8 Abbott Molecular: Biomarker Pipeline, 2015
Table 7.9 Agilent Technologies: Revenue ($bn) by Business Segment 2013-2015
Table 7.10 Myriad Genetics: Biomarker Product Portfolio, 2015
Table 7.11 Myriad Genetics: Revenue ($bn), and Revenue Shares (%) by Sector, 2013-2015
Table 7.12 bioMérieux : Revenue (€bn), ($bn) and AGR (%), 2010-2015
Table 7.13 bioMérieux: Revenue ($m) and Revenue Change (%) by Region, 2014-2015
Table 7.14 bioMérieux: Revenue ($bn) and Revenue Change (%) by Technology, 2014-2015
Table 7.15 Thermo Fisher Scientific: Revenue Sales ($bn), AGR (%) by Business Sector, 2012-2015
Table 7.16 Thermo Fisher Scientific: Revenue ($bn), Revenue Share (%) by Geography, 2013-2015
Table 8.1 SWOT Analysis of the Companion Diagnostics Market, 2016-2026
Table 9.1 Theranostics and Other In Vitro Diagnostics: Global Sales Forecast ($bn), 2014, 2020 and 2026

List of Figures
Figure 1.1 Companion Diagnostics: Overview of Submarkets
Figure 2.1 Development of Biomarkers into Companion Diagnostics, 2015
Figure 3.1 The World IVD Market: Market Share (%) in the IVD Market, 2014
Figure 3.2 The World CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2014-2025
Figure 3.3 The World IVD and CDx Market: Revenue ($bn), AGR (%) and CAGR (%), 2014-2026
Figure 3.4 The World CDx Market Share (%) in the IVD Market, 2020
Figure 3.5 The World CDx Market Share (%) in the IVD Market, 2026
Figure 3.6 The World Companion Diagnostics Market: Market Share (%) by Submarket, 2014
Figure 3.7 The World CDx Market by Submarket: Revenue ($bn) and AGR (%) 2014-2026
Figure 3.8 The World CDx Market Share (%) in the IVD Market, 2020
Figure 3.9 The World CDx Market Share (%) in the IVD Market, 2026
Figure 3.10 The CDx Market: Market Shares (%) by Sector in the IVD Market, 2014
Figure 4.1 The Leading National Markets for CDx by Sales ($bn), 2014
Figure 4.2 The Leading National Markets for CDx by Market Share (%), 2014
Figure 4.3 The Leading National Markets for CDx by Market Share (%), 2020
Figure 4.4 The Leading National Markets for CDx by Market Share (%), 2026
Figure 4.5 The US CDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 4.6 The EU5 Leading National Markets for CDx by Revenue ($bn), 2014
Figure 4.7 The EU5 Leading National Markets for CDx by Market Share (%), 2014
Figure 4.8 The EU5 National Markets for CDx by Market Share (%), 2020
Figure 4.9 The EU5 National Markets for CDx by Market Share (%), 2026
Figure 4.10 The German CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.11 The French CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.12 The Italian CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.13 The Spanish CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.14 The UK CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.15 The Japanese CDx Market Forecast: Revenue ($bn) and AGR (%), 2014-2026
Figure 4.16 The Chinese CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.17 The Indian CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.18 The Brazilian CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.19 The Russian CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.20 The South Korean CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 4.21 The Rest of the World CDx Market Forecast: Revenue ($bn) and AGR (%) 2014-2026
Figure 6.1 Current Business Models for the Development of Companion Diagnostics, 2016
Figure 6.2 Stakeholders in the Companion Diagnostics Market, 2016
Figure 7.1 Roche Diagnostics: Revenues ($bn) by Business Area, 2014
Figure 7.2 Roche Diagnostics: Revenue Share (%) by Business Area, 2014
Figure 7.3 Roche Diagnostics: Revenue Share (%) by Geography, 2014
Figure 7.4 Qiagen: Revenue ($bn), Net Income ($bn) and Profit Margin (%), 2010-2015
Figure 7.5 Qiagen: Revenue Share (%) by Geography, 2015
Figure 7.6 Abbott Laboratories: Historical Revenue ($m), 2012-2015
Figure 7.7 Abbott Laboratories: Revenue Share (%) by Business Sector, 2015
Figure 7.8 Agilent Technologies: Revenue ($bn) by Business Segment 2013-2015
Figure 7.9 Myriad Genetics: Revenue ($m), Net Income ($m) and Profit Margin (%), 2011-2013
Figure 7.10 bioMérieux: Revenue ($bn) and AGR (%), 2010-2015
Figure 7.11 bioMérieux: Revenue ($bn) by Region, 2014
Figure 7.12 bioMérieux: Revenue Share (%) by Region, 2015
Figure 7.13 bioMérieux: Revenue Share (%) by Technology, 2015
Figure 7.14 Thermo Fisher Scientific: Revenue Sales ($bn) by Business Sector, 2015
Figure 7.15 Thermo Fisher Scientific: Revenue Share (%) by Geography, 2015
Figure 8.1 Drivers and Restraints in the Companion Diagnostics Market, 2016-2026
Figure 8.2 Porter’s Five Analysis of the Companion Diagnostics Market, 2016-2026
Figure 9.1 Theranostics and Other In Vitro Diagnostics: World Sales Forecast ($bn), 2014, 2020 and 2026

【レポートのキーワード】

コンパニオン診断(CDx)、体外診断用医薬品、バイオマーカー、医薬品

★調査レポート[コンパニオン診断(CDx)の世界市場予測2016-2026] ( The Companion Diagnostics (CDx) Market Forecast 2016-2026 / VGAIN6041538) 販売に関する免責事項
[コンパニオン診断(CDx)の世界市場予測2016-2026] ( The Companion Diagnostics (CDx) Market Forecast 2016-2026 / VGAIN6041538) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆